Genflow Biosciences is advancing its lead therapy, GF-1002, which delivers a SIRT6 gene variant linked to longevity, currently in a 12-month proof-of-concept trial in aged dogs that began in March 2025.

In 2025, the company plans to start a clinical trial to evaluate GF-1002's potential in treating metabolic dysfunction-associated steatohepatitis, a chronic liver disease lacking effective treatments.

Preliminary safety data from Genflow’s ongoing GF-1004 study in aging dogs has shown no adverse events, supporting the therapy’s safety profile in this segment.

Genflow is forming collaborations to accelerate commercialization by leveraging partner resources, regulatory expertise, and infrastructure, which helps reduce execution risks.

These collaborations are part of Genflow’s broader strategy to develop its SIRT6-centenarian gene therapy platform for both human and animal health applications.

The company has signed two Confidential Disclosure Agreements with major animal health companies to facilitate data sharing and explore potential collaborations in the animal health market.

Genflow aims to evaluate partnerships focused on extending healthspan and improving quality of life in companion animals, a rapidly growing and lucrative market segment.